Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.23750/abm.v91i3.9796 http://scihub22266oqcxt.onion/10.23750/abm.v91i3.9796 32921751!7717025!32921751     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=32921751&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Acta+Biomed 2020 ; 91 (3): e2020002 Nephropedia Template TP {{tp|p=32921751|t=2020. Elevated transaminases in a COVID-19 positive patient at term of gestation: a case report |pdf=|usr=}}{{32921751}} gab.com Text Elevated transaminases in a COVID-19 positive patient at term of gestation: a case report JO: Acta Biomed http://www.kidney.de/pget.php?&tw=1&pmid=32921751 #FOAvip BACKGROUND: The coronavirus disease 2019 (COVID-19) pandemic is caused by the severe acute respiratory syndrome 2 virus (SARS-CoV-2) and it is spreading worldwide with an alarming high transmission rate. SARS-CoV-2 usually attacks the lungs causing a wide range of symptoms ranging from mild dyspnea to severe shortness of breath requiring intubation. Elevation of liver transaminases in the patients' sera has been described in up to 53% of the COVID-19 positive patients. The underlying pathogenic mechanisms of the virus on the liver cells are unclear and only few hypotheses are currently available. Data on COVID-19 in pregnant women are lacking and the management of COVID-19 pregnant women is challenging. An elevation of the transaminases during pregnancies infected by SARS-CoV-2 has never been described before. METHODS: Here we presented the case of a 29 years-old patient at 38 weeks of gestation COVID-19 positive with elevated transaminases. RESULTS: The patient showed a progressive decrease of transaminases after the delivery of the fetus. We provided details about the daily transaminases trend, the therapy used and the maternal/neonatal outcomes. CONCLUSIONS: We speculate that in our case the delivery of the fetus contributed to the normalization of the liver enzymes. In patients affected by COVID-19, at term of gestation, with elevated transaminases, delivery of the fetus is an appealing option. If confirmed by larger studies, our proposed management might be incorporated in the obstetrical management guidelines for COVID-19 positive patients. Twit Text FOAVip Elevated transaminases in a COVID-19 positive patient at term of gestation: a case report ????Acta Biomed http://www.kidney.de/pget.php?&tw=1&pmid=32921751 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32921751 #FOAvip English Wikipedia <ref>{{Cite pmid|32921751}}</ref> Elevated transaminases in a COVID-19 positive patient at term of gestation: a case report #MMPMID32921751 Nkeih C; Sisti G; Schiattarella A Acta Biomed 2020[Sep]; 91 (3): e2020002 PMID32921751show ga BACKGROUND: The coronavirus disease 2019 (COVID-19) pandemic is caused by the severe acute respiratory syndrome 2 virus (SARS-CoV-2) and it is spreading worldwide with an alarming high transmission rate. SARS-CoV-2 usually attacks the lungs causing a wide range of symptoms ranging from mild dyspnea to severe shortness of breath requiring intubation. Elevation of liver transaminases in the patients' sera has been described in up to 53% of the COVID-19 positive patients. The underlying pathogenic mechanisms of the virus on the liver cells are unclear and only few hypotheses are currently available. Data on COVID-19 in pregnant women are lacking and the management of COVID-19 pregnant women is challenging. An elevation of the transaminases during pregnancies infected by SARS-CoV-2 has never been described before. METHODS: Here we presented the case of a 29 years-old patient at 38 weeks of gestation COVID-19 positive with elevated transaminases. RESULTS: The patient showed a progressive decrease of transaminases after the delivery of the fetus. We provided details about the daily transaminases trend, the therapy used and the maternal/neonatal outcomes. CONCLUSIONS: We speculate that in our case the delivery of the fetus contributed to the normalization of the liver enzymes. In patients affected by COVID-19, at term of gestation, with elevated transaminases, delivery of the fetus is an appealing option. If confirmed by larger studies, our proposed management might be incorporated in the obstetrical management guidelines for COVID-19 positive patients. |*Betacoronavirus[MESH] |Adult[MESH] |Biomarkers/blood[MESH] |COVID-19[MESH] |Cesarean Section[MESH] |Coronavirus Infections/diagnosis/*enzymology/epidemiology[MESH] |Female[MESH] |Gestational Age[MESH] |Humans[MESH] |Infant, Newborn[MESH] |Lung/*diagnostic imaging[MESH] |Pandemics[MESH] |Pneumonia, Viral/diagnosis/*enzymology/epidemiology[MESH] |Pregnancy[MESH] |Pregnancy Complications, Infectious/diagnosis/*enzymology[MESH] |Pregnancy Outcome[MESH] |Radiography, Thoracic[MESH] |SARS-CoV-2[MESH]Elevated transaminases in a COVID-19 positive patient at term of gesta(epmc).pdf DeepDyve Pubget Overpricing